Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk

Irene A Abela^{1

2}, Frédérique Chammartin³, Alain Amstutz^{3

4

5}, Bernard Surial⁶, Marie Ballif^{6

7}, Catia Marzolini^{8

9}, Karoline Aebi-Popp⁶, Julia Notter¹⁰, Olivier Segeral¹¹, Marcel Stoeckle⁹, Matthias Cavassini¹², Enos Bernasconi¹³, Huldrych F Günthard^{1

2}, Roger D Kouyos^{1

2}, Chloé Pasin^{1

2}; Swiss HIV Cohort Study

Collaborators, Affiliations

Collaborators

Swiss HIV Cohort Study:
I Abela, K Aebi-Popp, A Anagnostopoulos, M Battegay, E Bernasconi, D L Braun, H C Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, C A Fux, H F Günthard, A Hachfeld, D Haerry, B Hassec, H H Hirsch, M Hoffmann, I Hösli, M Huber, D Jackson-Perry, C R Kahlert, O Keiser, T Klimkait, R D Kouyos, H Kovari, K Kusejko, N Labhardt, K Leuzinger, B Martinez de Tejada, C Marzolini, K J Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, G Pantaleo, M Perreau, A Rauch, L Salazar-Vizcaya, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, M Weisser, S Yerly

Affiliations

¹ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
² Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
³ Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
⁴ Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, University of Oslo, Oslo, Norway.
⁵ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
⁶ Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁷ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁸ Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁹ Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
¹⁰ Clinic for Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
¹¹ HIV Unit, Infectious Diseases Department, Geneva University Hospital, Geneva, Switzerland.
¹² Infectious Diseases Service, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
¹³ Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.

PMID: 39296341
PMCID: PMC11409876
DOI: 10.1093/ofid/ofae502

Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk

Irene A Abela et al. Open Forum Infect Dis. 2024.

. 2024 Sep 9;11(9):ofae502.

doi: 10.1093/ofid/ofae502. eCollection 2024 Sep.

Authors

Collaborators

Swiss HIV Cohort Study:
I Abela, K Aebi-Popp, A Anagnostopoulos, M Battegay, E Bernasconi, D L Braun, H C Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, C A Fux, H F Günthard, A Hachfeld, D Haerry, B Hassec, H H Hirsch, M Hoffmann, I Hösli, M Huber, D Jackson-Perry, C R Kahlert, O Keiser, T Klimkait, R D Kouyos, H Kovari, K Kusejko, N Labhardt, K Leuzinger, B Martinez de Tejada, C Marzolini, K J Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, G Pantaleo, M Perreau, A Rauch, L Salazar-Vizcaya, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, M Weisser, S Yerly

Affiliations

¹ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
² Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
³ Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
⁴ Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, University of Oslo, Oslo, Norway.
⁵ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
⁶ Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁷ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁸ Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁹ Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
¹⁰ Clinic for Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
¹¹ HIV Unit, Infectious Diseases Department, Geneva University Hospital, Geneva, Switzerland.
¹² Infectious Diseases Service, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
¹³ Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.

PMID: 39296341
PMCID: PMC11409876
DOI: 10.1093/ofid/ofae502

Abstract

The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD risk are less likely to receive statins than cisgender men. Efforts are needed to guarantee equal access to statin-based CVD prevention.

Keywords: Cardiovascular prevention; gender disparities; people with HIV; prescription; statin.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interests. I.A.A. has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences, and a grant from the Promedica foundation. R.D.K. has received research fundings from Gilead unrelated to this work. K.A.P.'s institution has received travel grants and advisory fees from MSD, Gilead, and ViiV healthcare unrelated to this work. H.F.G. has received grants from the SNF, SHCS, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, viral disease; Zurich Primary HIV Infection; Bill and Melinda Gates Foundation; National Institutes of Health; Gilead Sciences, ViiV Healthcare; and Roche; and personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson, and Novartis, for consultancy or DSMB membership and a travel grant from Gilead. C.M. received speaker honoraria from Gilead and ViiV unrelated to this work. M.S. received advisory fees from Gilead, MSD, Moderna, Pfizer, and ViiV healthcare unrelated to this work and a travel grant from Gilead. E.B.'s institution received research grants from SHCS, Swiss National Science Foundation, Gilead, and Merck; advisory fees and travel grants from Gilead, Merck, ViiV, Pfizer, Abbvie, Moderna, Astra Zeneca, and Ely Lilly unrelated to the present work. B.S. reports support to his institution for travel grants from Gilead Sciences and ViiV healthcare, and for advisory boards from MSD.

Figures

**Figure 1.**
Adjusted hazard ratios and 95% confidence intervals (CI) for statins prescriptions by gender (cisgender women vs cisgender men) and ethnicity (people of Black, Hispano-American, and Asian ethnicity vs White ethnicity) in each CVD risk category: low/moderate (blue), high (yellow), and very high (red)). CVD risk was calculated using the SCORE2 or SCORE2-OP. Adjusted for age (per 10 y), intravenous drug use (yes/no), education level (mandatory school or less vs apprenticeship or any degree), body mass index (less than 18.5, between 18.5 and 25, between 25 and 30, and more than 30 kg/m²), living alone (yes/no), current smoker (yes/no; imputed from the most recent value available if missing), physical activity (more vs less than twice a month), previous exposure to protease inhibitors, diabetes, non-HDL value (total cholesterol minus HDL), and family history of CVD. CM, cisgender men, CW, cisgender women.

See this image and copyright information in PMC

References

1. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS 2016; 11:492–500. - PMC - PubMed
1. Nüesch R, Wang Q, Elzi L, et al. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). JAIDS 2013; 62:396–404. - PubMed
1. Periard D, Cavassini M, Taffé P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46:761–7. - PubMed
1. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 2023; 389:687–99. - PMC - PubMed
1. Todd JV, Cole SR, Wohl DA, et al. Underutilization of statins when indicated in HIV-seropositive and seronegative women. AIDS Patient Care STDS 2017; 31:447–54. - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk

Collaborators

Affiliations

Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources